# Junta clínica — PT-pseudo_0615b2bd8504 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_0615b2bd8504",
  "pid": "PT-pseudo_0615b2bd8504",
  "task": 1,
  "psa": 160.0,
  "age": 63,
  "months": 1,
  "pirads": "5",
  "psad": 2.635,
  "psav": 35.73,
  "psap": 115.9,
  "vol": 60.71,
  "dre": "Abnormal",
  "bx": "Positive",
  "cspca": 0.95889634,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 160 ng/mL. PI-RADS 5. PSAD 2.63. Prostate volume 61 mL. DRE abnormal. csPCa 0.96.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "93 kg",
    "height": "191 cm",
    "bmi": "25.5",
    "bp": "140/81 mmHg",
    "hr": "48 bpm",
    "smoking": "Current smoker (20 pack-yr)",
    "last_dental": "2 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "26 Jan 2025",
  "enc_ref": "Dr. C. Peters (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent elevation in PSA levels alongside a history of biopsy-confirmed prostate adenocarcinoma warrants clinical reassessment."
    },
    {
      "s": "History",
      "t": "Now aged 63-year-old, the individual works as a retired bank clerk and Lives in ground-floor apartment with partner. Following an initial PSA measurement of 55.0 ng/mL in late 2022, a prior biopsy bucket \"Positive\" was documented. He maintains a Married status and engages in light resistance training twice weekly, complemented by a moderate alcohol intake of 14 units per week. Current smoker (20 pack-yr) status is noted, though he explicitly denies haematuria, pelvic discomfort, or lower urinary tract symptoms exceeding a baseline IPSS of 10. Past medical reviews include a routine hearing evaluation, an orthopaedic check for stable knee osteoarthritis, and a memory clinic assessment revealing intact cognition. He has never utilized 5-alpha-reductase inhibitors. General health remains excellent with an ECOG performance status of 0. Comorbidities: none. Active medication: None."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm and irregular nodule palpable in the left posterior peripheral zone; mobility: fixed; asymmetry: pronounced enlargement with right lobe induration but no distinct discrete masses; overall classification: cT3a. Abnormal DRE confirmed. Vital signs record a blood pressure of 140/81 mmHg and a resting heart rate of 48 bpm. General survey shows no palpable lymphadenopathy or hepatosplenomegaly."
    }
  ],
  "occupation": "retired bank clerk",
  "marital": "Married",
  "living": "Lives in ground-floor apartment with partner",
  "next_of_kin": "Sibling (brother)",
  "recent_other": [
    "Audiology — hearing test",
    "Orthopaedic outpatient — knee follow-up",
    "Memory clinic — baseline screening"
  ],
  "alcohol": "14 units / week",
  "exercise": "Light weight-training at home, 2x/week",
  "ipss": "IPSS score: 10/35 (moderate LUTS)",
  "admin": "Patient self-employed; flexible appointment slots requested.",
  "mri_hospital": "Amsterdam UMC (location AMC)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_0615b2bd8504
Task: 1

Encounter: Urology - outpatient on 26 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 160.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 2.635 ng/mL²
  - PSA velocity: 35.73 ng/mL/yr
  - Prior PSA: 115.9 ng/mL
  - Prostate volume: 60.71 mL
  - Months since last PSA: 1
  - DRE findings: Abnormal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.95889634 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 160 ng/mL. PI-RADS 5. PSAD 2.63. Prostate volume 61 mL. DRE abnormal. csPCa 0.96.

Vitals: weight 93 kg, height 191 cm, BMI 25.5, BP 140/81 mmHg, HR 48 bpm. Smoking: Current smoker (20 pack-yr).

Chief complaint: Persistent elevation in PSA levels alongside a history of biopsy-confirmed prostate adenocarcinoma warrants clinical reassessment.

History: Now aged 63-year-old, the individual works as a retired bank clerk and Lives in ground-floor apartment with partner. Following an initial PSA measurement of 55.0 ng/mL in late 2022, a prior biopsy bucket "Positive" was documented. He maintains a Married status and engages in light resistance training twice weekly, complemented by a moderate alcohol intake of 14 units per week. Current smoker (20 pack-yr) status is noted, though he explicitly denies haematuria, pelvic discomfort, or lower urinary tract symptoms exceeding a baseline IPSS of 10. Past medical reviews include a routine hearing evaluation, an orthopaedic check for stable knee osteoarthritis, and a memory clinic assessment revealing intact cognition. He has never utilized 5-alpha-reductase inhibitors. General health remains excellent with an ECOG performance status of 0. Comorbidities: none. Active medication: None.

Physical examination: DRE — texture: firm and irregular nodule palpable in the left posterior peripheral zone; mobility: fixed; asymmetry: pronounced enlargement with right lobe induration but no distinct discrete masses; overall classification: cT3a. Abnormal DRE confirmed. Vital signs record a blood pressure of 140/81 mmHg and a resting heart rate of 48 bpm. General survey shows no palpable lymphadenopathy or hepatosplenomegaly.

Patient info: retired bank clerk; Married; Lives in ground-floor apartment with partner.
Next of kin: Sibling (brother).

Lifestyle: alcohol 14 units / week; exercise Light weight-training at home, 2x/week; IPSS score: 10/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test; Orthopaedic outpatient — knee follow-up; Memory clinic — baseline screening.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.40
  uncertainty  +/- 0.18 epistemic (95% band 0.04-0.75); among patients I cannot tell apart the outcome was 0.97 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = none recorded (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 63 (2% of my signal; from age) · DRE = Abnormal (10% of my signal; from dre_suspicious) · PSA = 160 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 60.71 mL (1% of my signal; from log_vol, vol) · PSA density = 2.635 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.96 (1% of my signal; from cspca) · PI-RADS = 5 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. My criterion answers DEFER.

The criterion: PSA >= 20 ng/mL in a man with a tissue diagnosis: the next step is staging and treatment, not more tissue. In the labelled series this criterion matched the reading urologist in 5 of 6 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  decisive   PSA = 160 ng/mL
  important  prior biopsy = Positive
  noted      age = 63 · DRE = Abnormal · prostate volume = 60.71 mL · PSA density = 2.635 · PI-RADS = 5 · comorbidity = none recorded
  not used   family history, csPCa probability
CONFIDENCE: uncertain — the rule matched the reading urologist in only 5 of 6 labelled cases

## Intervención 5 — EXPERT-EXPERIENCE

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

I recall 48 men I have seen in this same situation (Positive prior biopsy). The 3 most similar patients, and what the reading urologist did:
  1. distance 0.72: PI-RADS 5, PSA 190.0, PSAD 4.097, age 66, DRE Nodus -> DEFER (clear). He wrote: "Patient with a clear PCa diagnosis. Do PSMA-PET and start hormontreatment"
  2. distance 0.79: PI-RADS 5, PSA 113.0, PSAD 2.61, age 67, DRE Nodus -> DEFER (clear). He wrote: "Patient has a verified PCa with PSA 113. Start treatment and do I PSMA-PET for further workup."
  3. distance 1.74: PI-RADS 5, PSA 187.0, PSAD 3.26, age 75, DRE Nodus -> BIOPSY (clear). He wrote: "Very High PSA. Most likely metastatic"

PRECEDENT: DEFER (weighted vote 0.18 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What my professional experience contributes: it shows what this urologist looks at and how he phrases the call. These memories do not establish facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  decisive   prior biopsy = Positive · PSA = 160 ng/mL · PI-RADS = 5
  noted      family history = not opened (0 of 91) · age = 63 · DRE = Abnormal · prostate volume = 60.71 mL · PSA density = 2.635 · comorbidity = none recorded
  not used   csPCa probability
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  decisive   prior biopsy = Positive · PI-RADS = 5
  important  age = 63 · PSA = 160 ng/mL
  noted      family history = not opened (0 of 91) · DRE = Abnormal · prostate volume = 60.71 mL · PSA density = 2.635 · comorbidity = none recorded
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines suggest that the decision to perform a biopsy should be guided by a risk-adapted matrix involving PI-RADS score and PSA density. The retrieved text states, "linking PI-RADS score (1-2, 3, and 4-5) to PSA-D categories (< 0.10, 0.10-0.15, 0.15-0.20 and > 0.20ng/mL) (Table 5.5) [230]." This requires assessing the patient's PSA density against these thresholds to guide the decision.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your variable 'prior biopsy = Positive' is decisive, whereas the guideline treats this as context; the guideline requires assessing the patient's PSA density against the risk matrix. The guideline suggests that for patients with PI-RADS 5 and PSA-D > 0.20 ng/mL/cc, a biopsy is indicated, which is a specific threshold the panel variables do not fully represent. The guideline needs the patient's PSA density value to determine the appropriate risk category.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: Positive means the guideline suggests staging and treatment, not more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA trend: the guideline requires assessing the PSA density against the risk matrix to determine the appropriate risk category.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

The case hinges on whether the PSA density value, which the EAU guideline emphasizes, is sufficient to override the context provided by the prior positive biopsy.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the mpMRI prose indicate if the lesion is compared against an earlier study?
  psa_trend (get_psa_trend) -> What is the PSA trend to assess the patient's PSA density against the risk matrix?
  previous_notes (get_previous_notes) -> What is the prior biopsy status, and is there a surveillance protocol or treatment already planned?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. Given the prior positive biopsy, does the previous notes indicate a surveillance protocol is in place, or is treatment already agreed upon?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "What is the PSA density value to determine the appropriate risk category according to the EAU guideline?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Prostate Multiparametric MRI | Date: 20 January 2025 | Facility: Amsterdam UMC (AMC)
COMPARISON: new
LESION: PI-RADS 5 lesion in the left peripheral zone with suspected extracapsular extension.

psa_trend
PSA trend: PSA 14.8 (Aug 2022), PSA 18.9 (Jun 2023), PSA 12.0 (Apr 2024), PSA 160.0 (Jan 2025).

previous_notes
PRIOR GRADE: Gleason 3+4 pathology
BIOPSY SESSIONS: 1, on 31 May 2024
SURVEILLANCE: expedited outpatient urology visit was scheduled for advanced imaging and procedural planning.
TREATMENT: expedited outpatient urology visit was scheduled for advanced imaging and procedural planning.

WHAT I DID NOT OPEN
family-history anamnesis, because it was not requested by the plan and is not critical to the immediate decision based on the opened documents.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 lesion with suspected extracapsular extension from radiology_report.
PSA density of 2.635 ng/mL/mL, which is > 0.20 ng/mL/cc, supporting biopsy per EAU guideline context.

AGAINST sampling this patient now
Prior positive biopsy status from previous_notes suggests staging and treatment, not more tissue.

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (clear). Last value 160.00 ng/mL over 4 points spanning 29 months; velocity +51.87 ng/mL per year; doubling time about 10 months.
PROJECTION at 6 months: 618.3 ng/mL, conformal 95% band 177.4-2155.0.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  important  PSA = 160 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: clear — the conformal band clears the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.40
  uncertainty  +/- 0.17 epistemic (95% band 0.07-0.73), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 5 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      PSA = 160 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 60.71 mL (4% of my signal; from log_vol, vol) · PSA density = 2.635 (0% of my signal; from psad_calc) · comorbidity = none recorded (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, DRE, csPCa probability
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.40  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.40  ('discuss' tier, fusion_nolab; weight 1.5)
  EXPERT-EXPERIENCE  DEFER, p(biopsy)=0.18  (k=3 precedents; does not vote)
  EXPERT-COHORT      DEFER  (rule psa_ge_20; does not vote)

  documented prior grade in the opened documents: GG 2 ("Gleason 3+4")

RULE THAT FIRED: cohort criterion (psa_ge_20) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 5 of 6 labelled cases in exactly this situation (prior positive biopsy).

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:DEC E2:—            -> decisive
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          63                           E1:not E3:— cohort:not library:not E2:—              -> important
  dre          Abnormal                     E1:not E3:— cohort:not library:not E2:—              -> not_used (raised from noted by the board)
  psa          160 ng/mL                    E1:not E3:not cohort:DEC library:DEC E2:IMP          -> important
  vol          60.71 mL                     E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         2.635                        E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.96                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       5                            E1:not E3:IMP cohort:not library:DEC E2:—            -> decisive
  comorbidity  none recorded                E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes) have addressed the moderator's questions by providing the prior biopsy status, a surveillance protocol, and the PSA trend.

ALIGNMENT WITH THE PANEL
The retrieved evidence is mixed. The `previous_notes` state that an expedited outpatient urology visit was scheduled for advanced imaging and procedural planning, which aligns with the panel's context suggesting staging/treatment, but the `radiology_report` indicates a PI-RADS 5 lesion with suspected extracapsular extension, which supports the guideline-based indication for biopsy.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Given the prior positive biopsy, does the previous notes indicate a surveillance protocol is in place, or is treatment already agreed upon? The `previous_notes` indicate an expedited outpatient urology visit was scheduled for advanced imaging and procedural planning, which is not explicitly a surveillance protocol or agreed treatment plan.

WHAT CARRIES WEIGHT, AND WHY
psa: important: 160 ng/mL (important) because the panel protocol weighted this as important, and the PSA trend is rising, which Expert-PSA noted as clear.
pirads: decisive: 5 (decisive) because the panel protocol marked this as decisive, and the EAU guideline emphasizes the PI-RADS score in the risk matrix.
prior biopsy: decisive: Positive (decisive) because the panel protocol marked this as decisive, but the EAU guideline suggests this context should be weighed against PSA density.
MY SUGGESTION TO THE CHAIR
I suggest a biopsy. The EAU guideline, as noted by Expert-EAU, suggests a biopsy when PI-RADS 5 and PSA-D > 0.20 ng/mL/cc, which the registrar noted supports. This finding overrides the context of the prior positive biopsy, as per the guideline's risk matrix.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

63y/o, PSA 160, PSAD 2.635, PI-RADS 5, prior positive biopsy (Gleason 3+4). High PSA and prior documented high grade dictate staging and treatment over repeat biopsy. The PI-RADS 5 finding is consistent with known disease progression, making further tissue sampling inappropriate. Staging and treatment plan required.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
